# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-166747
Filing Date
2026-04-21
Accepted
2026-04-21 16:05:36
Documents
14
Period of Report
2026-04-21

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | evmn-20260421.htm iXBRL | DEF 14A | 954141
2 | GRAPHIC | img41218707_0.gif | GRAPHIC | 4027
3 | GRAPHIC | img41218707_1.jpg | GRAPHIC | 472105
4 | GRAPHIC | img41218707_2.jpg | GRAPHIC | 203792
| Complete submission text file | 0001193125-26-166747.txt |  | 2736630

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | evmn-20260421.xsd | EX-101.SCH | 7527
17 | EXTRACTED XBRL INSTANCE DOCUMENT | evmn-20260421_htm.xml | XML | 6625

Mailing Address 1891 PAGE MILL RD PALO ALTO CA
Business Address 1891 PAGE MILL RD PALO ALTO CA (650) 223-7745
Evommune, Inc. (Filer) CIK: 0002044725 (see all company filings)

EIN.: 850742575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-42938 | Film No.: 26879421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)